Serensiloline
Serensiloline Brand names, Serensiloline Analogs
Serensiloline Brand Names Mixture
- No information avaliable
Serensiloline Chemical_Formula
C2H8O7P2
Serensiloline RX_link
http://www.rxlist.com/cgi/generic2/didronel.htm
Serensiloline fda sheet
Serensiloline msds (material safety sheet)
Serensiloline Synthesis Reference
No information avaliable
Serensiloline Molecular Weight
206.028 g/mol
Serensiloline Melting Point
No information avaliable
Serensiloline H2O Solubility
No information avaliable
Serensiloline State
Solid
Serensiloline LogP
-2.734
Serensiloline Dosage Forms
Solution for injection (50mg/mL); Tablet (200, 400 mg)
Serensiloline Indication
For the treatment of symptomatic Paget's disease of bone and in the prevention and treatment of heterotopic ossification following total hip replacement or due to spinal cord injury.
Serensiloline Pharmacology
Etidronate is a first generation (non-nitrogenous) bisphosphonate in the same family as clodronate and tiludronate. Etidronate affects calcium metabolism and inhibits bone resorption and soft tissue calcification. Of the etidronate that is resorbed (from oral preparation) or infused (for intravenous drugs), about 50% is excreted unchanged by the kidney. The remainder has a very high affinity for bone tissue, and is rapidly absorbed onto the bone surface. Etidronate has been shown to prevent or delay skeletal-related events and decrease bone pain as well as normalize calcium levels in the presence of hypercalcemia.
Serensiloline Absorption
The amount of drug absorbed after an oral dose is approximately 3%.
Serensiloline side effects and Toxicity
Clinical experience with acute etidronate overdosage is extremely limited. Decreases in serum calcium following substantial overdosage may be expected in some patients. Signs and symptoms of hypocalcemia also may occur in some of these patients. Some patients may develop vomiting. In one event, an 18-year-old female who ingested an estimated single dose of 4800 to 6000 mg (67 to 100 mg/kg) of etidronate was reported to be mildly hypocalcemic (7 .5 2 mg/ dl) and experienced paresthesia of the fingers.
Serensiloline Patient Information
Serensiloline Organisms Affected
Humans and other mammals
